In the past few years, paradigms for the treatment of low-grade glioma have shifted, owing to new diagnostic criteria and new clinical trial evidence. Here, Jan Buckner and colleagues discuss how molecular markers are challenging previous assumptions about low-grade glioma, and examine how new data will affect diagnostic testing, surgery, chemotherapy and radiation therapy for individuals with these tumours.
- Jan Buckner
- Caterina Giannini
- Robert Jenkins
